Research programme: cancer therapeutics - CiMass

Drug Profile

Research programme: cancer therapeutics - CiMass

Alternative Names: CIM 201; CIM 301; Natural killer cell engaging antibody - CiMass; Natural killer cell therapy - CiMass

Latest Information Update: 16 Nov 2016

Price : $50

At a glance

  • Originator CiMass
  • Developer Cancer Research Technology; CiMass; University of Copenhagen
  • Class Antibodies; Bispecific antibodies; Cell therapies
  • Mechanism of Action Immunostimulants; Natural killer cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Breast cancer; Cancer; Multiple myeloma

Most Recent Events

  • 16 Nov 2016 Preclinical trials in Breast cancer (Metastatic disease) in Netherlands (Parenteral)
  • 16 Nov 2016 Preclinical trials in Cancer in Netherlands (Parenteral)
  • 16 Nov 2016 Preclinical trials in Multiple myeloma in Netherlands (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top